TD Cowen Reiterates Buy Rating on AstraZeneca (AZN) Amid Potential 'Multi-Billion $ Opportunity'
Tweet Send to a Friend
TD Cowen analyst Steve Scala reiterated a Buy rating and $240.00 price target on AstraZeneca (NASDAQ: AZN).The analyst commented: "Positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
